- 1 Full Title: A Descriptive Study of a Clinical Pharmacist's Role in the Outpatient Pulmonary
- 2 Hypertension Clinic in the United States (CliPR-PH)
- 3 **Authors:** Vienica Funtanilla, PharmD¹, Dylan Lee², Eric Kim², Crystal Zhou, PharmD, APh, AHSCP,
- 4 BCACP³
- ⁵ ¹University of California, San Francisco Department of Clinical Pharmacy and Janssen Scientific
- 6 Affairs, ²University of California, San Francisco School of Pharmacy, ³University of California, San
- 7 Francisco School of Pharmacy and Department of Clinical Pharmacy
- 8 Short Title: CliPR-PH Study
- 9 **Corresponding author:**
- 10 Vienica Funtanilla (vienicafuntanilla@gmail.com)
- 11 521 Parnassus Avenue, Rm 3304, UCSF Box 0622
- 12 San Francisco, CA 94143
- 13 Total word count: 3272

14 Abstract

15	BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease affecting the heart and
16	lungs. Median survival was 2.8 years historically, but prognosis improved with the advances of
17	PAH therapy. It is currently not standard of care for clinical pharmacists to be a part of the
18	interdisciplinary care team in outpatient PH clinics to help manage patients' drug regimens, and
19	there is limited literature that has explored the impact of clinical pharmacists on patient-related
20	processes and outcomes. The goal of the CliPR-PH study is to characterize the activities of the
21	clinical pharmacist as a member of the interdisciplinary team.
22	METHODS: CliPR-PH was a retrospective, descriptive, single-center cohort study of patients ≥ 18
23	years, diagnosed with pulmonary hypertension, and managed by a clinical pharmacist practicing
24	under a collaborative practice agreement between January 1, 2018 and July 31, 2020. Patients
25	were excluded from the study if they were not on any PAH medications at the time of
26	pharmacist encounter.
27	RESULTS: Sixty patients were included in the analysis and 331 clinical pharmacist interventions
28	were documented over the study period. Interventions were regarding selexipag [88 (26.6%)],
29	sildenafil [74 (22.4%)], tadalafil [46 (13.9%)], prior authorization (PA) completions [127 (38.4%),
30	PA troubleshooting [43 (13.0%)], and 'Other' [49 (14.8%)].
31	CONCLUSION: Clinical pharmacists can play an important role in closely monitoring patients
32	during the medication titration phase and ensure prior authorizations are approved in a timely
33	manner as part of the interdisciplinary team in the outpatient PH clinic setting using a
34	collaborative practice model approach.

35 Key Words: collaborative practice, selexipag, titration, managing side effects

36 Clinical Perspective (required by Circulation, in 2-3 bullet points and 100 words max per

- 37 answer)
- 38 What is new?
- There are currently no studies in the United States that asses a clinical pharmacist's role
- 40 on the interdisciplinary team as part of a collaborative practice agreement in the
- 41 outpatient pulmonary hypertension (PH) clinic.
- 42 What are the clinical implications?
- 43 Integrating a clinical pharmacist on the medical team in an outpatient PH clinic setting
- 44 allows them to closely monitor patients who are titrating selexipag, manage adverse
- 45 events (AEs) that occur during the titration phase, and ensure medications requiring
- 46 prior authorizations are approved in a timely manner.

47 **INTRODUCTION**

Pulmonary hypertension (PH) is a disease that affects the heart and lungs and is classified into 5 groups. The approved drugs for PH are indicated for World Health Organization (WHO) Group 1, pulmonary arterial hypertension (PAH).¹ PAH is a rare disease with an estimated prevalence of 48 to 55 cases per million adults based on registry data from economically developed countries.¹ It is characterized by elevated pulmonary arterial pressure and assessed via right heart catheterization. Before targeted PAH therapy was available, the prognosis for PH was poor with a median survival of 2.8 years and estimated 1-year, 3-year, and 5-year survival rates

55	of 68%, 48%, and 34%, respectively, according to the NIH registry. The prognosis improved after
56	advances in PAH therapy in the 1990s, with 1-year, 3-year, 5-year, and 7-year survival rates of
57	85%, 68%, 57%, and 49%, respectively, according to patients enrolled in the REVEAL registry
58	between 2006 and 2009. ²
59	Treatment regimens for PAH tend to be complex, in part because there are five classes of
60	medications that are approved to treat PAH and they are frequently used in combination. ³ In
61	patients without cardiopulmonary comorbidities, the 2022 ESC/ERS Guidelines for the
62	treatment of PH recommend initial oral combination therapy in patients who are at low or
63	intermediate risk of death at 1 year and initial triple therapy with a parenteral agent in patients
64	at high risk of death at 1 year. ¹ In addition to targeted therapy, supportive therapy such as oral
65	anticoagulation, diuretics, digoxin, and management of anemia may also be warranted in
66	patients who experience other cardiovascular complications due to PAH. ^{1,4}
67	Due to the complexity of medication treatment in PAH patients, clinical pharmacists can play a
68	vital role as part of the interdisciplinary team. The different roles that clinical pharmacists can
69	play in the treatment of patients with PAH include formulary management, medication safety
70	such as the creation of medication order sets to lower chances of medication error, regulatory
71	compliance, patient and care provider support, medication access, side effect management,
72	drug interaction assessment, and transitions of care support. ^{4,5} It is currently not standard of
73	care for clinical pharmacists to be a part of the interdisciplinary care team in outpatient PH
74	clinics to help manage patients' drug regimens, and there is limited literature that has explored
75	the impact of clinical pharmacists on patient-related processes and outcomes. The goal of the

- 76 CliPR-PH study is to further characterize the activities of the clinical pharmacist as a member of
- 77 the interdisciplinary team.

78 Study design

- 79 CliPR-PH was a retrospective, descriptive, single-center cohort study of patients \geq 18 years,
- 80 diagnosed with PH, and managed by an interdisciplinary team that included a clinical
- 81 pharmacist between January 1, 2018 and July 31, 2020. The first date of encounter by the
- 82 clinical pharmacist was identified as the index date.

83 Methods

- Patients \geq 18 years of age with an established diagnosis of PH at the date of the first
- pharmacist's encounter, who had at least one clinic visit between January 1, 2018, to July 31,
- 86 2020, were included in the study (Figure 1). To identify the study cohort, a list of patients was
- 87 obtained from the University of California San Francisco (UCSF) Medical Center Information
- 88 Technology Services for patients seen between this time period, with PH or PAH (ICD-9 codes:
- 416.8, 747.83, 416.0, 416.8; ICD-10 codes: I27.20, P29.30, I27.2, I27.0, I27.24, I27.29, I27.21,
- 90 I27.23, I27.22), and who interacted with a clinical pharmacist at the UCSF outpatient PH center.
- 91 An encrypted spreadsheet was created that censored patient identifier information (medical
- 92 record number and name) to collect patient information and pharmacist interventions.
- 93 Interventions that were collected included medication changes (dose increase, switching
- 94 therapy, or discontinuation), prior authorizations, enrollment in patient assistance programs,
- 95 and side effect management. Patients were excluded from the study if they were not on any
- 96 PAH medications at the time of their pharmacist encounter. Chart review was conducted by DL,

- 97 EK, and SC and VF and CZ verified for accuracy. Descriptive statistics were conducted using
- 98 Microsoft Excel. This study was reviewed and approved by the WCG Institutional Review Board
- 99 (IRB# 21-35283) as an exempt study under 45 CFR 46.104(d)(4).

100 **RESULTS**

- 101 Study population and characteristics
- 102 Sixty patients met the inclusion criteria and were included in the analysis. Among the 60
- 103 patients, there were 331 documented clinical pharmacist interventions over the study period.
- 104 The study population at baseline consisted of patients with a mean age of 54 years, a higher
- number of females (60%), and predominantly WHO FC II and III (Table 1).

106 Pharmacist Interventions

107 The clinical pharmacist supported a diverse range of medications and medication issues. Out of 108 331 interventions, 88 (26.6%) interventions were regarding selexipag, 74 (22.4%) interventions 109 were regarding sildenafil, and 46 (13.9%) interventions were regarding tadalafil [Figure 2]. One-110 hundred twenty-seven (38.4%) pharmacist interventions were prior authorization (PA) 111 completions, 43 (13.0%) pharmacist interventions were PA troubleshooting, and 49 (14.8%) 112 pharmacist interventions were 'Other', [Figure 3]. 'Other' consisted of a variety of pharmacist 113 interventions including medication reconciliation, medication access troubleshooting not 114 related to insurance (i.e., bubble packs), phone calls to patients for lab reminders and to pharmacies for medication approval verification, blood pressure check, and blood pressure 115 machine troubleshooting. 116

117 DISCUSSION

The CliPR-PH study is the first study that examines clinical pharmacist work through a 118 collaborative practice agreement supporting PH patients in the United States. In France, Roustit 119 et al conducted a prospective, multicenter randomized controlled study that assessed the 120 impact of clinical pharmacists in the collaborative care of patients diagnosed with PH and were 121 122 on initial PH-specific (i.e., endothelin receptor antagonist, phosphodiesterase-5 inhibitors, prostacyclin analogs, or a combination of these drugs) and non-specific (i.e., diuretics and 123 anticoagulants) therapy between March 2010 and August 2012. Drug-related problems (DRP) 124 125 were more frequently resolved in the collaborative care group with a clinical pharmacist versus the standard of care group (86.5% vs 66.7%, p=0.01). Resolution of DRPs also translated into 126 reduced costs associated with DRP-related hospitalization. However, there was no 127 demonstrated difference in adherence, satisfaction with medication, and health-related quality 128 129 of life between groups. ⁶ Since the enrollment of patients between 2010 and 2012 in the Roustit 130 et al study, new treatments in PH emerged, specifically selexipag's approval in 2015. Selexipag 131 is a prostacyclin receptor agonist with a starting dose of 200 mcg twice daily and titrated to the highest tolerated dose, up to 1600 mcg twice daily.⁷ With the approval of selexipag, the role of 132 133 the clinical pharmacist has evolved. Selexipag requires dosing titration and clinical pharmacists have the expertise to closely monitor patients, perform dose titration strategies, and manage 134 135 AEs during the titration phase. Selexipag is also recommended as an add-on therapy to the 136 initial combination therapy per the 2022 ERS/ESC Guidelines, suggesting that patients on selexipag have more severe disease and are on more complex regimens. 137

Registry data shows that patients with PAH have a high chance of having a comorbid condition 138 139 along with their PAH diagnosis. In the SPHERE registry of patients who initiated selexipag in the 140 United States, 98.8% of 500 patients had at least one comorbidity and 55% were receiving combination therapy. Most patients at baseline were also WHO FC II (31%) and III (49.6%).⁸ In 141 our study, the most common medication that was involved the pharmacist's interventions was 142 selexipag and 46.7% of patients at baseline were WHO FC III, suggesting that the population of 143 patients encountered by the pharmacist had more severe disease and a more complex 144 145 medication regimen. Additionally in UCSF's collaborative practice agreement, patients are 146 referred to the pharmacist by the physician and usually, patients requiring referrals are those with more severe disease and whose treatments are more complex. Patients with more 147 148 complex medication regimens provide an opportunity for pharmacists to utilize their knowledge in multiple disease states and play a role in identifying drug interactions and 149 minimizing polypharmacy. 150

151 In patients who are initiating oral selexipag, there is a role for clinical pharmacists in the 152 outpatient setting to help with dose titration and manage AEs. Since the recommended starting dose of selexipag is 200 mcg twice daily and patients titrate usually at weekly intervals of 200 153 154 mcg twice daily to the highest tolerated dose up to 1600 mcg twice daily, it would take at least 7 weeks for a patient to reach the highest tolerated dose. The dose can also be reduced if 155 156 patients are not able to tolerate the titrated dose, which can take longer to reach the highest 157 tolerated dose.⁷ In a retrospective study conducted by Palevsky et al of specialty pharmacy data examining real-world dosing patterns of selexipag, 79% of 523 patients who had history of prior 158 159 prostacylin use and 87.1% of 3,408 patients who have no history of prior prostacyclin use

titrated slower than weekly intervals (>8 days/200 mcg twice daily).⁹ This suggests that titration 160 161 of selexipag is personalized per patient and clinical pharmacists as part of the interdisciplinary 162 medical team can closely monitor these patients to ensure they are titrating at an appropriate speed to reach their individual maintenance doses. In a real-world study conducted by Chang et 163 al of 113 Korean patients with PAH who initiated selexipag and were followed up for 24 weeks, 164 it was found that AEs occurred more often in the titration phase and that recovery rates were 165 65-77% with a median time to recovery of 15-70 days (range, 2-233 days). The median time to 166 167 resolution of an AE was 15 days for nausea/vomiting and about 2 months for diarrhea, myalgia, and headache.¹⁰ As highlighted by this data, the AEs associated with selexipag occur more often 168 in the titration phase and takes a few weeks to recover. Patients may not be willing to continue 169 170 taking a medication with AEs especially if they are not aware of what to expect. Clinical pharmacists can closely monitor patients on selexipag as they titrate to their maintenance dose 171 and help manage AEs. 172

173 In addition to closely monitoring patients during selexipag titration, the clinical pharmacist in 174 our study played an essential role in improving medication access for patients through facilitating insurance approval. Pharmacists are knowledgeable with the insurance approval 175 176 process and can use best practice for prior authorization approvals so that patients receive their medications in a timely manner. In a retrospective, single-center study on patients 177 178 diagnosed with PAH, Shah et al evaluated patients' adherence to phosphodiesterase-5 inhibitor 179 therapy within an integrated pharmacy practice model at an outpatient pulmonary clinic at an academic institution. The pulmonary clinic collaborated with a specialty pharmacy and 180 181 incorporated a clinical pharmacist and pharmacy technician as part of the healthcare team. In

the integrated care model, clinical pharmacists provided comprehensive medication 182 183 management, patient education, ongoing treatment monitoring, and assistance with transitions 184 of care. Shah et al found that for the 131 patients in their analysis, the mean proportion days 185 covered (PDC) was 96% (SD= 0.092), which is above the study's defined adherence threshold of 80% PDC.¹¹ The responsibilities of the pharmacist in this model are similar to the type of 186 187 interventions performed by the pharmacist in our study. The models slightly differ as our study used collaborative practice agreement between the physician and clinical pharmacist rather 188 189 than specialty pharmacy. The pharmacist's role differs between a specialty pharmacy model 190 and a collaborative care practice model. In a collaborative care practice model, such as our study, the clinical pharmacist played a role in managing dosing titration and closely monitoring 191 192 patients to ensure they tolerated the titration well. Collaborative care practice pharmacists can also work closely with physicians regarding recommendations and send prescriptions directly to 193 the pharmacy. This suggests that there could be a benefit to integrating pharmacists in the 194 195 outpatient PH clinic as they can improve dose titration tolerability, medication access, and higher touch points of care in patients with PAH. 196

197 Clinical pharmacists can play an important role as part of the interdisciplinary team in the 198 outpatient PH clinic setting using a collaborative care practice model approach. They can 199 manage titration of medication and adverse events in complex patients who may have more 200 severe PH and ensure prior authorizations are approved in a timely manner. Further research is 201 warranted to measure how clinical pharmacists' interventions lead to better outcomes, such as 202 medication adherence, patient persistence rates, and time and money saved as part of the 203 interdisciplinary team. Future research can also closely measure titration strategies and

204	duration by	y a clinical	pharmacist co	mpared to	the standard o	of care without	a clinical	pharmacist
-----	-------------	--------------	---------------	-----------	----------------	-----------------	------------	------------

205 on the interdisciplinary medical team and assess how that impacts patient outcomes.

206 Limitations

- 207 Limitations include the study design as a retrospective chart review, a small sample size from a
- single-center institution, descriptive data, and utilization of some baseline data that may not
- 209 have aligned with the index pharmacy visit date. While the results of our study may not be able
- to be generalized to all patients diagnosed with PAH at other centers, we hope the
- interventions of clinical pharmacists at our center can help inform program development in
- 212 other institutions.

213 Conclusions

- 214 Clinical pharmacists can play an important role in closely monitoring patients during the
- 215 medication titration phase and ensure prior authorizations are approved in a timely manner as
- 216 part of the interdisciplinary team in the outpatient PH clinic setting using a collaborative
- 217 practice model approach.

218 Acknowledgements

- 219 The authors would like to thank Sylvia Choi, for helping with chart reviews; Jennifer Cocohoba,
- 220 PharmD, for helping to review the manuscript; and the UCSF IT team for generating an initial list
- 221 of patients to begin chart reviews.

222 Sources of Funding

- 223 WCG IRB submission was funded by University of California, San Francisco, in which the authors
- were affiliated with at the time of analysis and writing of the study.

225 Author Disclosures

- 226 VF was a Post-Doctoral Fellow with Janssen Pharmaceuticals and UCSF at the time of analysis
- and writing of this study.

228 References

- 1. Humbert M, Kovacs G, Hoeper M, et al. 2022 ESC/ERS Guidelines for the diagnosis and
- treatment of pulmonary hypertension. *Eur Heart J*. 2022;00:1-114.
- 231 2. Lau EM, Giannoulatou E, Celermajer D, et al. Epidemiology and Treatment of
- Pulmonary Arterial Hypertension. *Nat Rev Cardiol*. 2017;14(10)Oct:603-614.
- 3. Lai Y, Potoka K, Champion H, et al. Pulmonary Arterial Hypertension. *Circ Res*. 2014; 115
- 234 (1): 115-130. doi: 10.1161/CIRCRESAHA.115.301146.
- 4. Macaulay TE, Covell MB, Pogue KT. An Update on the Management of Pulmonary
- Arterial Hypertension and the Pharmacist's Role. *J Pharm Pract*. 2015;29(1):67-76.
- doi:10.1177/0897190015615902.
- 238 5. Shane, R, Waldthausen, E, Kyle, J. Pharmacist's Role in Managing Pulmonary
- 239 Hypertension. *US Pharm*. 2023;48(2):HS-2-HS-5.
- 240 6. Roustit, M, Chaumais, M, Chapuis, C, Gairard Dory, A, et al. Evaluation of a collaborative
- 241 care program for pulmonary hypertension patients: a multicenter randomized trial. *Int J*
- 242 *Clin Pharm.* 2020;42(4), 1128-1138.
- 243 7. UPTRAVI[®] (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc.

244	8.	Kim NH, Hemnes AR, Chakinala MM, et al. Patient and disease characteristics of the first
245		500 patients with pulmonary arterial hypertension treated with selexipag in real-world
246		settings from SPHERE. J Heart Lung Transplant. 2021;40(4):279-288.
247	9.	Palevsky H, Pruett J, Ogbomo A, et al. Examining dosing patterns for selexipag in real-
248		world practice using US specialty pharmacy data. Poster presented at: Academy of
249		Managed Care Pharmacy (AMCP); April 21-24, 2020; Houston, TX.
250	10.	Chang SA, Lee SH, Choi JH, et al. Real-world practice patterns and characteristics of
251		adverse events with selexipag in Korean patients with pulmonary arterial hypertension.
252		Expert Opin Drug Saf. 2022. doi: 10.1080/14740338.2022.2069750. Epub.
253	11.	Shah, N, Mitchell, R, Proctor, ST, Choi, L, et al. High rates of medication adherence in
254		patients with pulmonary arterial hypertension: An integrated specialty pharmacy
255		approach. PLoS One. 2019;14(6). doi:10.137/journal.pone.0217798.

256 Table 1. Baseline characteristics

Characteristic	Patients (N = 60)				
Sex					
Female, n (%)	36 (60.0)				
Male, n (%)	24 (40.0)				
Age					
Mean ± SD	54.0 ± 14.89				
Distribution – n (%)	1				

< 65 years	45 (75.0)			
≥ 65 years	15 (25.0)			
BMI, kg/m2	28.7 ± 5.89			
SBP, mmHg	122.9 ± 19.44			
DBP, mmHg	71.9 ± 12.29			
HR, beats per minute	82.3 ± 14.43			
RR, breaths per minute	17.7 ± 2.01			
eGFR† (N=59), mL/min	78.5 ± 26.03			
BNP ⁺ (N=59), ng/L, median (range)	80 (5 – 1950)			
Insurance† (N=58), n (%)				
Federal Insurance (Medi-Cal/Medicare)	45 (77.6)			
Private Insurance	13 (22.4)			
Pericardial Effusion† (N=52), n (%)	9 (17.3)			
Predicted DLCO ⁺ (N=35), n (%)				
≤ 40%	11 (31.4)			
> 40%	24 (68.6)			
mRAP† (N=52), n (%)				
> 20 mmHg	0 (0.0)			
≤ 20 mmHg	52 (100.0)			
PVR† (N=52), n (%)				
< 5 WU	12 (23.0)			

WHO Functional Class, n (%) I 1 (1.7) II 25 (41.7) III 28 (46.7) IV 6 (10.0) Comorbidities, n (%) 446.7) Hypertension 28 (46.7) T2DM+ (N=42) 10 (23.8) Thyroid disorder+ (N=59) 10 (16.9) COPD 10 (16.7) Depression 9 (15.0) Sleep Apnea 17 (28.3) Family History – n (%) 46.8 Heart disease+ (N=27) 25 (92.6) Pulmonary hypertension ⁺ (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. *Total N does not equal to 60 due to missing data. Abbreviations: BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood	≥ 5 WU	40 (77.0)			
II 25 (41.7) III 28 (46.7) IV 6 (10.0) Comorbidities, n (%) 44.70 Hypertension 28 (46.7) T2DM+ (N=42) 10 (23.8) Thyroid disorder+ (N=59) 10 (16.9) COPD 10 (16.7) Depression 9 (15.0) Sleep Apnea 17 (28.3) Family History – n (%) 44.70 Heart disease+ (N=27) 25 (92.6) Pulmonary hypertension+ (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. *Total N does not equal to 60 due to missing data.	WHO Functional Class, n (%)				
III 28 (46.7) IV 6 (10.0) Comorbidities, n (%)	I	1 (1.7)			
IV 6 (10.0) Comorbidities, n (%) 440.000 Hypertension 28 (46.7) T2DM† (N=42) 10 (23.8) Thyroid disorder† (N=59) 10 (16.9) COPD 10 (16.7) Depression 9 (15.0) Sleep Apnea 17 (28.3) Family History – n (%) 25 (92.6) Pulmonary hypertension† (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. +Total N does not equal to 60 due to missing data.	II	25 (41.7)			
Comorbidities, n (%)Hypertension28 (46.7)T2DM† (N=42)10 (23.8)Thyroid disorder† (N=59)10 (16.9)COPD10 (16.7)Depression9 (15.0)Sleep Apnea17 (28.3)Family History – n (%)4000000000000000000000000000000000000	III	28 (46.7)			
Hypertension28 (46.7)T2DM+ (N=42)10 (23.8)Thyroid disorder+ (N=59)10 (16.9)COPD10 (16.7)Depression9 (15.0)Sleep Apnea17 (28.3)Family History – n (%)25 (92.6)Pulmonary hypertension+ (N=57)5 (8.8)Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may notequal to 100% due to rounding. +Total N does not equal to 60 due to missing data.	IV	6 (10.0)			
T2DM+ (N=42)10 (23.8)Thyroid disorder+ (N=59)10 (16.9)COPD10 (16.7)Depression9 (15.0)Sleep Apnea17 (28.3)Family History – n (%)25 (92.6)Pulmonary hypertension+ (N=57)5 (8.8)Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may notequal to 100% due to rounding. +Total N does not equal to 60 due to missing data.	Comorbidities, n (%)				
Thyroid disorder† (N=59)10 (16.9)COPD10 (16.7)Depression9 (15.0)Sleep Apnea17 (28.3)Family History – n (%)25 (92.6)Pulmonary hypertension† (N=57)5 (8.8)Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	Hypertension	28 (46.7)			
COPD 10 (16.7) Depression 9 (15.0) Sleep Apnea 17 (28.3) Family History – n (%) 4 Heart disease† (N=27) 25 (92.6) Pulmonary hypertension† (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	T2DM† (N=42)	10 (23.8)			
Depression9 (15.0)Sleep Apnea17 (28.3)Family History – n (%)Heart disease† (N=27)25 (92.6)Pulmonary hypertension† (N=57)5 (8.8)Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	Thyroid disorder† (N=59)	10 (16.9)			
Sleep Apnea 17 (28.3) Family History – n (%) 17 (28.3) Heart disease† (N=27) 25 (92.6) Pulmonary hypertension† (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	COPD	10 (16.7)			
Family History – n (%) Heart disease ⁺ (N=27) Pulmonary hypertension ⁺ (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. ⁺ Total N does not equal to 60 due to missing data.	Depression	9 (15.0)			
Heart disease ⁺ (N=27) 25 (92.6) Pulmonary hypertension ⁺ (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. +Total N does not equal to 60 due to missing data.	Sleep Apnea	17 (28.3)			
Pulmonary hypertension† (N=57) 5 (8.8) Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	Family History – n (%)				
Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not equal to 100% due to rounding. †Total N does not equal to 60 due to missing data.	Heart disease† (N=27)	25 (92.6)			
equal to 100% due to rounding. [†] Total N does not equal to 60 due to missing data.	Pulmonary hypertension ⁺ (N=57)	5 (8.8)			
	Notes: *Data is presented as mean ± SD unless otherwise indicated. Percentages may not				
Abbreviations: BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood	equal to 100% due to rounding. [†] Total N does not equal to 60 due to missing data.				
	Abbreviations: BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood				
pressure; HR=heart rate; RR=respiratory rate; eGFR=estimated glomerular filtration rate;					
BNP=B-type natriuretic peptide; DLCO=diffusing capacity for carbon monoxide; mRAP=mean					


right atrial pressure; PVR=pulmonary vascular resistance; WHO=World Health Organization;

T2DM=type II diabetes; COPD=chronic obstructive pulmonary disease; PH=pulmonary

hypertension; WU=Wood units.

257

258 Figure 1. Inclusion/Exclusion Criteria



260 Figure 2. Medications involved in pharmacist interventions




Figure 2. Medications involved in pharmacist interventions

Notes: None indicates that no medication was associated with the pharmacist intervention (i.e., Intervention was regarding medication reconciliation, lab reminders, etc.). Other indicates medication that were not PAH-targeted therapies.

*Selexipag is a prostacyclin receptor agonist. Treprostinil, iloprost, and epoprostenol are prostacyclin analogs. Abbreviations: ERA=endothelin receptor antagonist; PDE-5=phosphodiesterase-5.






Figure 3. Pharmacist interventions

Note: "Other" interventions included medication reconciliation, medication access troubleshooting not related to insurance (i.e., bubble packs), call reminders to patients, calls to pharmacies and insurance companies to verify medication approvals, blood pressure check, and blood pressure machine troubleshooting. **Abbreviations:** DDI=drug-drug interaction; PA=prior authorization; SE=side effect.